Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Thoracic Neoplasms » Respiratory Tract Neoplasms » Lung Neoplasms » Bronchial Neoplasms » Carcinoma, Bronchogenic » Carcinoma, Non-Small-Cell Lung
Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Lung Neoplasms » Carcinoma, Bronchogenic » Carcinoma, Non-Small-Cell Lung
Diseases [C] » Respiratory Tract Diseases [C08] » Respiratory Tract Neoplasms » Lung Neoplasms » Bronchial Neoplasms » Carcinoma, Bronchogenic » Carcinoma, Non-Small-Cell Lung
Description
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. MeSH
Hierarchy View
Approved Indicated Drugs (36)
Phase 4 Indicated Drugs (32)
Phase 2 Indicated Drugs (430)
2-(5-fluoro-pentyl)-2-methyl-malonic-acid
adenoviral vector expressing hsv-tk
allogeneic natural killer cells
autologous natural killer cells
autologous T cell memory cells
autologous tumor infiltrating lymphocytes
brentuximab vedotin (adcetris)
cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine
cd1c (bdca-1)+ / cd141 (bdca-3)+ mydc
gamma-glutamyl-s-(benzyl)-cysteinyl-r(-)-phenylglycine diethyl ester
human fecal microbiota (Reybota)
human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil)
hyaluronidase (human recombinant) (Hylenex)
hydroxychloroquine (plaquenil)
nitroglycerin (transderm-nitro)
personalized neoantigen vaccine
radiolabeled albumin technetium Tc-99m albumin colloid kit (Microlite)
Phase 1 Indicated Drugs (421)
99mtc ethylenedicysteine-deoxyglucose
autologous apd-l1 armored anti-cd22 car t cells
autologous dendritic cell adenovirus ccl21 vaccine
autologous dendritic cells loaded with autologous tumor lysate
autologous, engineered t cells targeting tp53 r175h
autologous genetically modified mage a4c1032 t cells
cxcr5 modified egfr chimeric antigen receptor autologous t cells
ex vivo-expanded her2-specific t cells
hla-a*0201 or hla-a*0206-restricted urlc10 peptides
hla-a*2402restricted urlc10, cdca1, and kif20a peptides
hla-a*2402restricted urlc10, cdca1, vegfr1 and vegfr2
Other Experimental Indicated Drugs (29)
Organization Involved with Phase 4 Indications (50)
Betta Pharmaceuticals Co.,Ltd.
Centre Georges Francois Leclerc
China Academy of Chinese Medical Sciences
Chinese Academy of Medical Sciences
Guangzhou Pharmaceucal Company Limited
Huazhong University of Science and Technology
Istituto Nazionale per lo Studio e la Cura dei Tumori
Organization Involved with Phase 3 Indications (345)
Australasian Lung Cancer Trials Group
Badalona Hospital Germans Trias i Pujol
Beijing Mabworks Biotech Co., Ltd.
BeyondSpring Pharmaceuticals Inc.
Blueprint Medicines Corporation
Bureau of Science and Technology of Guangxi Province, China
Cancer and Leukemia Group B (CALGB)
Cantonal Hospital of St. Gallen
Case Western Reserve University
Central and Eastern European Oncology Group
Central European Society for Anticancer Drug Research (CESAR)
Centre Hospitalier Intercommunal Creteil
Centro de Pesquisas Oncológicas - CEPON
Centus Biotherapeutics Limited
Chinese Society of Lung Cancer
Chinese Thoracic Oncology Group
Chinese University of Hong Kong
Dutch Society of Physicians for Pulmonology and Tuberculosis
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
European Lung Cancer Working Party
European Organisation for Research and Treatment of Cancer
European Thoracic Oncology Platform
Federation of Italian Cooperative Oncology Groups
Gottfried Wilhelm Leibniz Universität Hannover
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Groupe Francais De Pneumo-Cancerologie
Groupe Français de Pneumo-Cancérologie
Groupe Hospitalier Paris Saint Joseph
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Gruppo Oncologico del Nord-Ovest
Gruppo Oncologico Italia Meridionale
Gruppo Oncologico Italiano di Ricerca Clinica
Guangdong Academy of Medical Sciences
Guangdong Pharmaceutical University
Guangdong Province Clinical Trial Association
Hannover Clinical Trial Center GmbH
Hellenic Oncology Research Group
Hoosier Cancer Research Network
Icahn School of Medicine at Mount Sinai
Innovent Biologics (Suzhou) Co. Ltd.
Intergroupe Francophone de Cancerologie Thoracique
Japan Agency for Medical Research and Development
Japan Multinational Trial Organization
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
Jilin Provincial Tumor Hospital
King Faisal Specialist Hospital
Laboratorio Elea S.A.C.I.F. y A.
Memorial Sloan-Kettering Cancer Center
Nanjing Sanhome Pharmaceutical, Co., Ltd.
National Cancer Institute, France
National Cancer Institute (NCI)
National Center for Complementary and Integrative Health (NCCIH)
National Health and Medical Research Council, Australia
National Heart, Lung, and Blood Institute (NHLBI)
National Hospital Organization Osaka National Hospital
Niigata University Medical & Dental Hospital
North Central Cancer Treatment Group
Northwest Oncology Cooperative Group
Norwegian University of Science and Technology
Pacific Cancer Medical Center Inc.
Philipps University of Marburg
Radiation Therapy Oncology Group
Royal Marsden Hospital NHS Trust
Shaanxi Provincial People's Hospital
Shanghai Chest Hospital, Shanghai, China
Shanghai Gebaide Biotechnology Co., Ltd.
Shanghai Junshi Bioscience Co.,Ltd.
Shanghai Municipal Science and Technology Commission
Shanghai University of Traditional Chinese Medicine
Shanghai Yizhong Biotechnology Co., Ltd.
Shijiazhuang Pharma Group (CSPC)
State University of New York, Buffalo
State University of New York, Syracuse
The Christie NHS Foundation Trust
The Norwegian Lung Cancer Study Group
The University of Texas, Dallas
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
University of Alabama, Birmingham
University of California, San Diego
University of Campania Luigi Vanvitelli
University of Colorado, Denver
University of Electronic Science and Technology of China
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Texas at Houston
University of Western Australia
University of Western Brittany
Vita-Salute University of Milano. Italy
Organization Involved with Phase 2 Indications (587)
Academic and Community Cancer Research United
Acharya Tulsi Regional Cancer Treatment & Research Institute
Albert Einstein Israelite Hospital
Amphia Hospital Breda, the Netherlands
A.O. Ospedale di Circolo di Busto Arsizio
A.O. Ospedale di Circolo di Melegnano
A.O. Santa Maria Degli Angeli - Pordenone
A.O. Valtellina e Valchiavenna
Arbeitsgemeinschaft medikamentoese Tumortherapie
AUSL Piacenza - Ospedale Guglielmo da Saliceto
AUSL Viterbo - Ospedale di Belcolle
Autonomous University of Madrid
Azienda Ospedaliera Ospedale Civile di Legnano
Azienda Ospedaliera San Camillo Forlanini
Azienda Ospedaliera San Gerardo di Monza
Azienda Ospedaliera San Giovanni Battista
Azienda Ospedaliera Santa Maria Degli Angeli
Azienda Ospedaliera Sant'Andrea, Roma
Azienda Ospedaliera S. Maria della Misericordia
Azienda Ospedaliera Spedali Riuniti di Livorno, Livorno
Azienda Provinciale per i Servizi Sanitari della Provincia Autonoma di Trento
Azienda Sanitaria dell'Alto Adige
Azienda Sanitaria Locale n.2 Savonese
Bank of Cyprus Oncology Centre
Bankura Sammilani Medical College
Beijing Pearl Biotechnology Limited Liability Company
Benxi City hospital of Chinese medicine
Big Ten Cancer Research Consortium
Biotech Pharmaceutical Co., Ltd.
B.P. Poddar Hospital and Medical Research Ltd.
British Columbia Cancer Agency
Camargo Pharmaceutical Services
Cancer Research and Biostatistics Clinical Trials Consortium
Cancer Research Network of Nebraska
Cancer Therapeutics Research Group
Cancer Treatment Centers of America
Casa di Cura Dott. Pederzoli - Peschiera del Garda
Central European Cooperative Oncology Group
Centre Hospitalier de la Région d'Annecy
China Three Gorges University, Yichang, China
Chinese Lung Cancer Surgical Group
Chittaranjan National Cancer Institute
Choithram Hospital and Research Centre
Chongqing Precision Biotech Co., Ltd
City of Hope National Medical Center
Clifford Hospital, Guangzhou, China
Clinical Research Technology S.r.l.
Clinica Universidad de Navarra
Cyclacel Pharmaceuticals, Inc.
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
First Hospital of Shijiazhuang City
First People's Hospital of Yulin
Fondazione Ricerca Traslazionale
Frontier Science Foundation, Hellas
Gan and Lee Pharmaceuticals, USA
Gatot Subroto Central Army Hospital
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
GKNM Hospital, Coimbatore, India
Grupo de Investigación y Divulgación Oncológica
Grupo Gallego de Cancer de Pulmon
Grupo Portugues de Estudo do Cancro do Pulmao
Guangdong Province Association Study of Thoracic Oncology
Gujarat Cancer & Research Institute
Haemato-Onkologische Praxis und Tagesklinik
Haining Health-Coming Biotech Co., Ltd.
Hellenic Cooperative Oncology Group
Herbert Irving Comprehensive Cancer Center
HonorHealth Research Institute
Hospital General Universitario de Castellón
Hospital Universitario Arnau de Vilanova de Lleida
Hubei Clinical Research Collaboration Group
IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest
Indira Ghandhi Institute of Medical Science
Infinity Pharmaceuticals, Inc.
Institut de Cancérologie de la Loire (ICLN)
Institut de Cancerologie de l'Ouest Paul Papin
Institute of Oncology Dr. Rosell (IOR)
Institut für Klinische Krebsforschung IKF GmbH
Instituto Nacional de Enfermedades Respiratorias
Integrated Community Oncology Network
Istituto Clinico Humanitas - Rozzano (MI), Italy
Istituto Tumori Giovanni Paolo II, BARI
James Graham Brown Cancer Center
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Jiaxing Maternity and Child Health Care Hospital
Kanagawa Prefectural Cancer Center
Katholieke Universiteit Leuven
Kentucky Lung Cancer Research Program
Kobe Minimally Invasive Cancer Center
Korean South West Oncology Group
Latin American Cooperative Oncology Group
Laura & Isaac Perlmutter Cancer Center
Liaohe Oil Field General Hospital
Ludwig Institute for Cancer Research
Lung Cancer Research Foundation
Lungen Clinic Grosshansdorf, Grosshansdorf, Germany
Malabar Institute of Medical Sciences
Maria Sklodowska Curie Children's Hospital
Medigen Biotechnology Corporation
Methodist Cancer Center, Houston, Texas
Moorgreen Hospital, Southampton
Mt. Sinai Medical Center, Miami
National Cheng Kung University
National Comprehensive Cancer Network
National Hospital Organisation Nagoya Medical Centre
National Institutes of Health (NIH)
National University of Singapore
Netaji Subhash Chandra Bose Cancer Research Institute
Newish Technology (Beijing) Co.,Ltd.
New Mexico Cancer Care Alliance
North Sichuan Medical University
Olivia Newton-John Cancer Research Institute
Ospedale Santa Croce-Carle Cuneo
Ospedale Santa Maria della Misericordia
Ospedale San Vincenzo Taormina
Ospedale S. Giovanni Bellinzona
Ospedale S.M. della Misericordia
Owensboro Medical Health System
Personal Genome Diagnostics (PGDx)
Phoenix Clinical Research Center
Postgraduate Institute of Medical Education and Research
Prologue Research International
R.S.T. Cancer Hospital & Research Centre
Samyang Biopharmaceuticals Corporation
Shanghai EpimAb Biotherapeutics Co., Ltd.
Shenzhen Hank Bioengineering Institute
Shenzhen Hornetcorn Bio-technology Company, LTD
Shenzhen SiBiono GeneTech Co.,Ltd
Silvano Chiapparoli Logistica SpA
Singapore Clinical Research Institute
Southeastern Medical Oncology Center, Goldsboro
Southern Italy Cooperative Oncology Group
Southwestern Regional Medical Center
St. John Providence Health System
St. Joseph Hospital Health Center
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Swiss Group for Clinical Cancer Research
Taichung Veterans General Hospital
Taiwan Chest Disease Association
TAKO - Tiroler Arbeitskreis Onkologie
Technical University of Munich
The Chest Hospital of Anhui Province
The First Affiliated Hospital of Dalian Medical University
The First People's Hospital of Hangzhou
The First People's Hospital of Jingzhou
The First People's Hospital of Lianyungang
The People's Hospital of Liaoning Province
The Second People's Hospital of Sichuan
Translational Oncology Research International
Translational Research Informatics Center, Kobe, Hyogo, Japan
Trans Tasman Radiation Oncology Group
Universidad Complutense de Madrid
University of California, Berkeley
University of California, Davis
University of California, Irvine
University of California, Los Angeles
University of California, San Francisco
University of Illinois at Chicago
University of Medicine and Dentistry of New Jersey
University of Southern California
University of Southern Denmark
University of Technology, Sydney
University of Texas, San Antonio
Organization Involved with Phase 1 Indications (132)
Asbestos Diseases Research Foundation
BioNumerik Pharmaceuticals, Inc.
California Institute for Regenerative Medicine
Cancer Immunotherapy Trials Network
Center Trials & Treatment Inc.
Centro Integral Oncológica Clara Campal
Comprehensive Cancer Centers of Nevada
Guangdong Xiangxue Precision Medical Technology Co., Ltd
Guangzhou Bio-gene Technology Co., Ltd.
Guangzhou Xiangxue Pharmaceutical Co., Ltd
Hainan GeneralSanyang Pharmaceutical Co.,Ltd
Hemay Pharmaceutical PTY. LTD.
Hospital Privado De Santa Clara De Asis
Hospital Regional De Concepción
Hunan Provincal Tumor Hospital
Hunan Yongren Medical Innovation Co. Ltd.
Hunan Zhaotai Yongren Biotech Co. Ltd.
Jiangxi Provincial Cancer Hospital
National Hospital Organisation Kyushu Cancer Centre
National Institute for Health Research, United Kingdom
Northwest Cancer Specialists, P.C.
Oregon Health and Science University
Polyphenon E International,Inc.
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
Russian Academy of Medical Sciences
Organization Involved with Other Experimental Indications (18)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
